Patients with viral hepatitis, especially those with hepatitis cirrhosis, have poor body resistance and are prone to complicated tuberculosis infection. Tuberculosis is a wasting disease and recovery of liver function is more difficult in hepatitis patients without anti-tuberculosis treatment. Most anti-tuberculosis drugs have liver damaging effects. Improper use of anti-tuberculosis drugs can aggravate liver damage and even lead to liver failure. The type and dose of drugs should be adjusted when necessary according to the liver condition in HBV-infected patients with combined tuberculosis. 1, for elderly people with HBV infection, the dose of rifampin, pyrazinamide and other drugs with greater liver damage should be reduced. 2.Patients with mildly increased ALT should try isoniazid, streptomycin, ethambutol and other chemotherapy regimens with less strong effects on liver function on the basis of comprehensive liver protection and close observation of liver function, and the course of treatment can be extended appropriately. 3. For patients with cirrhosis and heavy hepatitis caused by HBV infection, drugs without obvious toxicity to the liver should be used as much as possible, such as streptomycin, butamycin, ethambutol, levofloxacin, etc. Isoniazid should be used with caution, and rifampin and pyrazinamide should be avoided. During anti-tuberculosis treatment, close observation should be made, liver function should be checked in time, liver-protective treatment should be strengthened in time when abnormalities are detected, and the dosage should be reduced or discontinued when necessary, and the treatment plan should be closely monitored and adjusted in time.